COMP <GO>
GYRE vs JNJ // REVENUE GROWTH (YOY)
Gyre Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: GYRE 3
— JNJ 9
▲ REVENUE GROWTH (YOY) LEADER: GYRE
LAST: $4.56 (-28.94%) • MKT CAP: $714.8M
revenue-growth
10.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.40% | 67.90% | +27.50 | GYRE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | 25.50% | -0.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.3x | 18.5x | +34.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | 2.97% | -3.00 | JNJ | /fcf-yield <GO> |
| Operating Margin | 9.90% | 34.70% | -24.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 8.50% | 28.50% | -20.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 10.20% | 6.00% | +4.20 | GYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 5.59 | +8.74 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 62.1 | -12.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | 23.0x | +44.20 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $714.8M | $662.49B | -$661.78B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | JNJ REV | GYRE GROSS % | JNJ GROSS % | GYRE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $94.19B | 95.4% | 67.9% | -$180.0K | $19.70B |
| FY 2024 | $105.8M | $88.82B | 96.3% | 69.1% | -$6.0M | $19.84B |
| FY 2023 | $113.5M | $85.16B | — | — | $25.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
JNJ // BETA 1.08